Want to see IN:LAURUSLABS full AI Analyst Report?
LAURUSLABS Stock Chart & Stats
₹1602.30
₹112.20(7.01%)
At close: 4:00 PM EDT
₹1602.30
₹112.20(7.01%)
Day’s Range― - ―
52-Week Range₹810.75 - ₹1,858.95
Previous CloseN/A
Volume7.99M
Average Volume (3M)107.31K
Market Cap
₹981.15B
Enterprise Value₹560.82K
Total Cash (Recent Filing)₹1.14B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)89.7
Beta0.97
Next Earnings
Oct 22, 2026EPS Estimate
5.58Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)20.25
Shares Outstanding540,249,600
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,700.00Price Target Upside6.10% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)24.69
Revenue Forecast (FY)₹83.30B
Bulls Say, Bears Say
Bulls Say
Improving ProfitabilityA rebound in net margin to ~13% and an EBITDA margin around 26% indicate the company is regaining operating leverage and pricing or cost control traction. Sustained mid-teens net margins support durable earnings power and greater ability to service debt and fund reinvestment over months.
Improving Leverage And Balance-sheet TrendA falling debt-to-equity ratio reflects manageable and improving leverage, supported by a rising equity base. This structural improvement increases financial flexibility, reduces covenant/default risk, and provides capacity for selective capex or M&A over the medium term.
Diversified Business Model With CDMO CapabilityExposure to APIs, finished dosages and CDMO services spreads revenue across product sales and higher-value contract manufacturing. CDMO capabilities create longer-term customer relationships, recurring project fees and potential margin tailwinds from specialized chemistry and scale.
Bears Say
Weak Free Cash Flow / Cash ConversionPersistent weak free cash flow and a sharp YoY decline limit the firm's ability to self-fund capex, reduce debt, or return capital. Reliance on operating cash that lags accounting earnings increases sensitivity to margin shocks and constrains strategic optionality over the medium term.
Gross Margin CompressionA structural drop in gross margin versus historical levels suggests sustained input-cost pressure, pricing erosion, or adverse mix shift. Lower gross margins compress operating leverage, making earnings more vulnerable and requiring sustained efficiency gains to restore prior profitability.
Choppy Revenue Growth ProfileErratic revenue performance—recovering after prior declines—signals demand or commercial execution variability. Continued volatility in top-line growth makes long-range planning and capacity utilization harder, raising execution risk for margin and cash-flow stability.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹810.75 and its highest was ₹1858.95 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹981.15B.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 77 days.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Jul 24, 2026. The company reported ₹6.8 earnings per share for the quarter, beating the consensus estimate of ₹4.912 by ₹1.888.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Undervalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Semiannually dividend of ₹1.2 which represents an annual dividend yield of 0.11%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 5.58.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 540,249,600 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹6.8 in its last earnings report, beating expectations of ₹4.912. Following the earnings report the stock price went up 2.168%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
LAURUSLABS Stock 12 Month Forecast
Average Price Target
₹1,700.00
▲(6.10% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―







